Business
Cue Biopharma, Inc.: This report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates.
Revenue increased 195.7% to $27.5M, while Net income increased 34.6% to ($26.6M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $27.5MWatch
- Profitability — Net income ($26.6M)Watch
- Cash generation — Free cash flow ($21.9M)Note
- Accounting — Formula distress score · manipulation flag raised · earnings quality greyWatch
- Insiders — 1 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Leadership changes
From Cue Biopharma, Inc.'s own filings, the day they're filed.
- Michael Meluzio · President · appointmenteff. 2026-06-01
- Sumita Ray · Chief Legal & Compliance Officer · appointmenteff. 2026-06-01
- Daniel Camardo · directors · departureeff. 2026-05-30
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-10
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cue Biopharma, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.